Wearable Device Tracks Movement in Adults With Neuromuscular Diseases or Obesity
Follows adults with neuromuscular or metabolic conditions, tracking their movement using a wearable device.
Plain-language title generated from the registry record
Registry title: Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Key facts
- Where
- Liège, BelgiumSee the site
Where in Belgium
- Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la CitadelleLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Liege
- Trial code
- NCT07136844
- Record updated
- 22 August 2025
- Original description
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.Read full original descriptionShow less
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.
Inclusion: Ambulant patients (i.e. able to walk 10 meters without assistance); Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.); Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination; Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV; Patient with morbid obesity (Body Mass Index> or = 35 at inclusion visit); Signed informed consent form by patient him/herself and patient willing and able to comply with all study procedures.
Exclusion: Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs; A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion; Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed; Non-ambulant patients; Patients who are participating in an interventional clinical trial; Pregnant or breastfeeding women.